The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma

AIDS

Volumn 16, Issue 17, 2002, Pages 2344-2347

  Esdaile, Ben ^a   Davis, Matt ^a   Portsmouth, Simon ^a   Sarker, Debashis ^a   Nelson, Mark ^a   Gazzard, Brian ^a   Bower, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIRETROVIRUS AGENT; CACLYX; DAUNORUBICIN; DOXORUBICIN; LIPOSOME; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CELL LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; KAPOSI SARCOMA; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; LIPOSOMES; MALE; MIDDLE AGED; SARCOMA, KAPOSI; T-LYMPHOCYTE SUBSETS; VIRAL LOAD;

EID: 0037159935     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200211220-00019     Document Type: Article

References (18)

1. Gill PS, Wemz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996, 14:2353-2264.
2. Northfeit DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial. J Clin Oncol 1998, 16: 2445-2451.
3. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998, 16:683-691.
4. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000, 92:1823-1830.
5. Conant MA, Opp KM, Poretz D, Mills RG. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir. AIDS 1997, 11:1300-1301.
6. Murphy M, Armstrong D, Sepkowitz KA, et al. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. AIDS 1997, 11:261-262.
7. Vaccher E, di Gennaro G, Nasti G, et al. HAART is effective as anti-Kaposi's sarcoma therapy only after remission has been induced by chemotherapy. J Acquir Immune Defic Syndr 1999, 22:407-408.
8. Winceslaus J. Regression of AIDS-related pleural effusion with HAART. Highly active antiretroviral therapy. Int J STD AIDS 1998, 9:368-370.
9. Osman M, Kubo R, Gill J, et al. Identification of HHV-8 specific cytotoxic T cell responses. J Virol 1999, 73:6136-6140.
10. Esber E, DiNicola W, Movassaghi N, Leikin S. T and B lymphocytes in leukaemia therapy. Am J Hematol 1976, 1:211-218.
11. Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994, 84:2221-2228.
12. Cheson B. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995, 13:2431-2448.
13. Hakim FT, Cepeda R, Kaimei S, et al. Constraints on CD4 recovery post chemotherapy in adults. Blood 1997, 90:3789-3798.
14. Komada YZS, Zhou YW, Hanada M, Shibata T, Azuma E, Sakurai M. Cellular immunosuppression in children with acute lymphoblastic leukaemia: Effect of consolidation chemotherapy. Cancer Immunol Immunother 1992, 35:271-276.
15. British HIV Association. Guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Co-ordinating Committee. Lancet 1997, 349:1086-1092.
16. British HIV Association (BHIVA). Guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001, 2:276-313.
17. Bower M, Fox P, Fife K, et al. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999, 13:2105-2011.
18. Powles I, Imami N, Nelson M, et al. The effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV associated lymphoma. AIDS 2002, 16:531-536.